A-share announcement, good news, Zhongsheng Pharmaceutical and other five companies issued important announcements.
1. Central Plains Expressway: toll revenue in January 40.2 billion yuan.
Zhongyuan Expressway announced that the toll revenue in January 2024 was 402,093,62148 yuan.
2. China Nuclear Power: Unit 3 of Zhangzhou Nuclear Power Plant poured the first tank of concrete on the nuclear island on the 22nd.
China Nuclear Power announced that the No. 3 unit of the Zhangzhou Nuclear Power Plant in Fujian Province, which is controlled and invested by the company, plans to pour the first tank of concrete (FCD) on the nuclear island on February 22. Unit 3 of Zhangzhou Nuclear Power Plant adopts the "Hualong No. 1" nuclear power technology with China's independent intellectual property rights, and the rated capacity of a single unit is 12120,000 kilowatts, the design operating life of the power station is 60 years. After the FCD of the unit, the number of nuclear power units under construction controlled by the company will reach 11, and the installed capacity will reach 126320,000 kilowatts
3. Xiangyu Medical: net profit in 2023300 million yuan, a year-on-year increase of 8296%
Siangyu Medical released a performance report, achieving a total operating income of 74.5 billion yuan, a year-on-year increase of 5246%；Net profit 2300 million yuan, a year-on-year increase of 8296%；Basic earnings per share was 146 yuan. During the reporting period, the company continued to enrich the first-class product line, and at the same time strengthened the layout of the marketing network and the construction of the marketing system, achieved the growth of sales orders, and drove the rapid growth of the company's net profit.
4. Zhongsheng Pharmaceutical: The first subject was enrolled in the phase II clinical trial of RAY1225 injection for overweight and obese patients.
Zhongsheng Pharmaceutical announced that the company's holding subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology***, independently developed a class of innovative peptide drug RAY1225 injection, has simultaneously launched two phase II clinical trials for patients with type 2 diabetes and overweight obesity in February 2024, and recently completed the enrollment of the first subject in the phase II clinical trial of overweight obesity.
5. Guobo Electronics: net profit of 6 in 20230.6 billion yuan, a year-on-year increase of 1645%
Guobo Electronics announced the 2023 annual performance express report, and during the reporting period, the company achieved a total operating income of 356.7 billion yuan, an increase of 308%；Net profit attributable to owners of the parent company was realized60.6 billion yuan, an increase of 16 over the same period last year45%。